Additionally, molecular receptors mediating the HIF1 pathway are the primary targets for tyrosine-kinase–inhibiting targeted therapies (TT), which are frequently used in metastatic ccRCC [8]. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.